An application to include a drug to treat the early symptoms of Alzheimer's disease on the Pharmaceutical Benefits Scheme (PBS) has been rejected. The committee in charge of making the decision has ruled the potential benefits of the drug donanemab are too small, and the burden for both patients and the health system too large. In other news, a new study has highlighted the benefits of lifestyle interventions in staving off cognitive decline in people at high risk. ReferencesPharmaceutical Benefits Advisory Committee (PBAC) Meeting Outcomes - July 2025Allostatic Load and Racial and Rural Disparities in Breast Cancer Survival | Oncology | JAMA Network Open | JAMA NetworkStructured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related